Palatin Technologies, Inc.: Palatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update
Phase 2 obesity co-administration study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatide Database lock completed Topline data readout ...
Zacks.com on MSN7h
LLY Rises More Than 4% in a Week: How to Play the Stock
Eli Lilly and Company’s LLY shares have risen 4.3% since it reported fourth-quarter results on Feb. 6. Lilly’s fourth-quarter ...